Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) Revenue (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Revenue data on record, last reported at $164.7 million in Q4 2025.

  • For Q4 2025, Revenue fell 22.75% year-over-year to $164.7 million; the TTM value through Dec 2025 reached $1.7 billion, up 322.15%, while the annual FY2025 figure was $1.7 billion, 114.51% up from the prior year.
  • Revenue reached $164.7 million in Q4 2025 per PTCT's latest filing, down from $211.0 million in the prior quarter.
  • Across five years, Revenue topped out at $1.2 billion in Q1 2025 and bottomed at -$210.1 million in Q2 2024.
  • Average Revenue over 5 years is $215.8 million, with a median of $187.7 million recorded in 2023.
  • Peak YoY movement for Revenue: crashed 198.27% in 2024, then soared 459.73% in 2025.
  • A 5-year view of Revenue shows it stood at $165.2 million in 2021, then grew by 1.32% to $167.4 million in 2022, then soared by 83.41% to $307.1 million in 2023, then tumbled by 30.58% to $213.2 million in 2024, then decreased by 22.75% to $164.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $164.7 million in Q4 2025, $211.0 million in Q3 2025, and $178.9 million in Q2 2025.